ROIV ROIVANT SCIENCES LTD Operational Disruptions 8-K Filing 2023 - Press Release Roivant Sciences Ltd. issued a press release announcing initial data from Immunovant's Phase 2 clinical trial in Graves disease, showing positive results and potential best-in-class IgG reduction.Get access to all SEC 8-K filings of the ROIVANT SCIENCES LTD